Once-daily Preservative-free Topical Anti-glaucomatous Monotherapy – A Better Approach?

Toby S Al-Mugheiry; David C Broadway;  ;  ;

doi:10.17925/eor.2020.14.1.21

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation

Advances in Therapy ◽

10.1007/s12325-021-01801-y ◽

2021 ◽

Author(s):

Dolores Ochoa ◽

Manuel Román ◽

Carmen Belmonte ◽

Samuel Martín-Vilchez ◽

Gina Mejía-Abril ◽

...

Keyword(s):

Once Daily ◽

Preservative Free ◽

Ophthalmic Formulation

Download Full-text

Timogel® vs Timolol 0.5% Ophthalmic Solution: Efficacy, Safety, and Acceptance

European Journal of Ophthalmology ◽

10.5301/ejo.5000006 ◽

2011 ◽

Vol 22 (1) ◽

pp. 28-33 ◽

Cited By ~ 9

Author(s):

Teresa Rolle ◽

Daniela Curto ◽

Camilla Alovisi ◽

Mauro Franzone ◽

Beatrice Brogliatti ◽

...

Keyword(s):

Intraocular Pressure ◽

Side Effects ◽

Open Angle Glaucoma ◽

Ophthalmic Solution ◽

Previous Treatment ◽

Hypotensive Effect ◽

Schirmer Test ◽

Blurred Vision ◽

Once Daily ◽

Preservative Free

Purpose To evaluate the efficacy, safety, and tolerability of Timogel® preservative-free once daily compared to timolol 0.5% ophthalmic solution bid in patients with ocular hypertension (OHT) and patients with primary open-angle glaucoma (POAG). Methods A total of 75 patients with OHT and patients with POAG treated with timolol 0.5% bid with intraocular pressure (IOP) ≤21 mmHg were enrolled. They underwent complete ophthalmologic examination, IOP measurements (at trough and daytime curve), evaluation of side effects, Schirmer test, break-up time [BUT], blood pressure, heart rate, ocular diastolic perfusion pressure measurements, and acceptance (Comparison of Ophthalmic Medications for Tolerability). Patients switched to Timogel® and were re-evaluated 3 months later. The analysis of variance and the Pearson χ2 tests were used to test differences between the treatments. Results Intraocular pressure reduction at trough was 23.6% with timolol 0.5% and 22.3% with Timogel®. No statistical differences were observed in IOP values at trough and in the daytime curve between the 2 treatments. Local and systemic side effects were less frequent with Timogel® (hazard ratio: p<0.05). Patients demonstrated a significant improvement of Schirmer test and BUT (p<0.05) and a reduction of dryness and foreign body sensation (42.6% vs 15.4%; p<0.01) after switching to Timogel®. Mild and short-lasting blurred vision after Timogel® instillation occurred in about 18.5% of patients. A total of 82% of patients were satisfied or very satisfied with Timogel® vs 61% with previous treatment (p<0.01). Conclusions Timogel® preservative-free dosed once every morning has a 24-hour hypotensive effect with a better safety profile than timolol 0.5% bid and it is well-accepted by patients. The once-daily dosing improved acceptance and compliance.

Download Full-text

The effect of bromocriptine on mammary-gland ultrastructure of hyperprolactinemic rats

Proceedings, annual meeting, Electron Microscopy Society of America ◽

10.1017/s0424820100111136 ◽

1984 ◽

Vol 42 ◽

pp. 204-205

Author(s):

I.C. Murray

Keyword(s):

Mammary Gland ◽

Dopamine Agonist ◽

Alveolar Epithelium ◽

Mammary Glands ◽

Female Rats ◽

Control Group ◽

Cell Hyperplasia ◽

Once Daily ◽

Long Evans

In women, hyperprolactinemia is often due to a prolactin (PRL)-secreting adenoma or PRL cell hyperplasia. RRL excess stimulates the mammary glands and causes proliferation of the alveolar epithelium. Bromocriptine, a dopamine agonist, inhibits PRL secretion and is given to women to treat nonpuerperal galactorrhea. Old female rats have been reported to have PRL cell hyperplasia or adenoma leading to PRL hypersecretion and breast stimulation. Herein, we describe the effect of bromocriptine and consequently the reduction in serum PRL levels on the ultrastructure of rat mammary glands.Female Long-Evans rats, 23 months of age, were divided into control and bromocriptine-treated groups. The control animals were injected subcutaneously once daily with a 10% ethanol vehicle and were later divided into a normoprolactinemic control group with serum PRL levels under 30 ng/ml and a hyperprolactinemic control group with serum PRL levels above 30 ng/ml.

Download Full-text

3H-galactose and 3H-glucose incorporation into newly synthesized hepatic glycogen in control-fed rats

Proceedings, annual meeting, Electron Microscopy Society of America ◽

10.1017/s0424820100143080 ◽

1986 ◽

Vol 44 ◽

pp. 292-293

Author(s):

J.E. Michaels ◽

S.A. Garfield ◽

J.T. Hung ◽

S.S. Smith ◽

R.R. Cardell

Keyword(s):

Biochemical Analysis ◽

Glycogen Synthesis ◽

Hepatic Glycogen ◽

Electron Microscopic ◽

Once Daily ◽

Tail Vein ◽

Tracer Dose ◽

Glucose Incorporation ◽

Wet Weight

3H-galactose (gal) and 3H-glucose (glu) were compared to determine which compound was preferable for pulse labeling newly formed hepatic glycogen. Control fed rats were used to achieve substantial and consistent levels of hepatic glycogen and to stimulate glycogen synthesis.Rats fed once daily for 4 hr achieved hepatic glycogen levels > 3% wet weight liver prior to injection by tail vein of a tracer dose of 3H-gal or 3H-glu. The rats were sacrificed 15-120 min later and liver was prepared by routine techniques for light (LM) and electron microscopic (EM) radioautography (RAG) and biochemical analysis.

Download Full-text